Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H23N3O2 |
Molecular Weight | 337.4155 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1NC2=C(C=CC=C2)N1C3CCN(CCOC4=CC=CC=C4)CC3
InChI
InChIKey=NVDBBGBUTKLRSN-UHFFFAOYSA-N
InChI=1S/C20H23N3O2/c24-20-21-18-8-4-5-9-19(18)23(20)16-10-12-22(13-11-16)14-15-25-17-6-2-1-3-7-17/h1-9,16H,10-15H2,(H,21,24)
Oxiperomide was developed as a dopamine-receptor antagonist. Clinical trials have shown that this drug decreased dyskinesia in patients with Parkinson's disease receiving levodopa or other dopamine agonists without necessarily increasing Parkinsonian symptoms. However, information about the further development of this drug is not available.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7373324
Oxiperomide was given in 5 mg tablet doses twice daily, starting at 10 mg/day and increasing weekly by 5-10 mg/day intervals, up to 40 mg/day, until an optimal dose was achieved or side effects developed.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C38149
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
WRO75M6RW2
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
C66270
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
68634
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
313681
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL2059304
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
SUB09534MIG
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
100000083046
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
DTXSID30201306
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
3451
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
5322-53-2
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
C015411
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY